ONO-AG-367

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H30F2O6
Molecular Weight	440.4775
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)COC3=C(F)C=CC(F)=C3)[C@@]1([H])CC[C@H](CCCC(O)=O)CO2

InChI

InChIKey=PRIYCPZIGUYJAL-PRDSGWKNSA-N

InChI=1S/C23H30F2O6/c24-15-5-9-19(25)22(10-15)31-13-16(26)6-8-17-18-7-4-14(2-1-3-23(28)29)12-30-21(18)11-20(17)27/h5-6,8-10,14,16-18,20-21,26-27H,1-4,7,11-13H2,(H,28,29)/b8-6+/t14-,16+,17+,18+,20+,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C23H30F2O6
Molecular Weight	440.4775
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:37:02 UTC 2023` Edited by `admin` on `Sat Dec 16 10:37:02 UTC 2023`
Record UNII	T70C4DX25X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ONO-AG-367

Common Name

English

2H-CYCLOPENT(B)OXEPIN-3-BUTANOIC ACID, 6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-YL)OCTAHYDRO-7-HYDROXY-, (3S,5AR,6R,7R,8AS)-

Systematic Name

English

4-((3S,5AR,6R,7R,8AS)-6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-YL)-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOIC ACID

Systematic Name

English

4-((3S,5AR,6R,7R,8AS)-6-((E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-BUT-1-ENYL)-7-HYDROXY-3,4,5,5A,6,7,8,8A-OCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOIC ACID

Systematic Name

English

Code System Code Type Description

CAS

1262873-48-2

Created by admin on Sat Dec 16 10:37:02 UTC 2023 , Edited by admin on Sat Dec 16 10:37:02 UTC 2023

PRIMARY

FDA UNII

T70C4DX25X

Created by admin on Sat Dec 16 10:37:02 UTC 2023 , Edited by admin on Sat Dec 16 10:37:02 UTC 2023

PRIMARY

PUBCHEM

68749980

Created by admin on Sat Dec 16 10:37:02 UTC 2023 , Edited by admin on Sat Dec 16 10:37:02 UTC 2023

PRIMARY

Related Record Type Details


					7L8YW0VG16

PROSTAGLANDIN E2 RECEPTOR EP3 SUBTYPE

TARGET -> AGONIST

Qualification:

EC50

Amount:


					5NTX6739W3

PROSTAGLANDIN F2-ALPHA RECEPTOR

TARGET -> AGONIST

Qualification:

EC50

Amount:

Related Record Type Details


					79O7855J4G

SEPETAPROST

PRODRUG -> METABOLITE ACTIVE

Amount:

Related Record Type Details


					T70C4DX25X

ONO-AG-367

ACTIVE MOIETY

Comments:

1. The objectives of this phase I study were to assess the safety, tolerability, systemic pharmacokinetics (PK), and pharmacodynamics (PD) profiles of ONO-9054 (Sepetoprost), the prodrug of ONO-AG-367, in healthy, normotensive adults. 2. Class: Eye disorder therapy; Mechanism of Action: Prostaglandin E EP3 receptor agonist and Prostaglandin F2 alpha agonist: Highest Development Phase: Phase II Ocular hypertension Open-angle glaucoma; Most Recent Event: 01 Dec 2014 Ono Pharmaceutical completes a phase II trial for Ocular hypertension and Open angle glaucoma in USA (NCT02083289) 3. Post-hoc analysis of the results showed that nearly 90% of patents who had received doses of 10 un-defined g/mL or higher had IOP measurements of 18 mm Hg or lower following treatment

Amount: